Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED (CSL)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Securities Exc…
08/10/2018 08/13/2018 08/14/2018 08/15/2018 08/16/2018 Date
202.63(c) 202.3(c) 201.69(c) 214.58(c) 216.67 Last
611 768 634 942 900 389 1 331 150 1 497 981 Volume
+1.01% -0.16% -0.30% +6.39% +0.97% Change
More quotes
Financials (USD)
Sales 2019 8 462 M
EBIT 2019 2 613 M
Net income 2019 1 956 M
Debt 2019 3 260 M
Yield 2019 1,30%
Sales 2020 9 095 M
EBIT 2020 2 917 M
Net income 2020 2 217 M
Debt 2020 2 908 M
Yield 2020 1,47%
P/E ratio 2019 35,79
P/E ratio 2020 31,86
EV / Sales2019 8,70x
EV / Sales2020 8,05x
Capitalization 70 322 M
More Financials
Company
CSL Ltd. is a biopharmaceutical company.It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions.The company operates its business through two segments: CSL Behring and bioCSL.The CSL Behring segment provides... 
Sector
Pharmaceuticals
Calendar
08/15Earnings Release
More about the company
Surperformance© ratings of CSL Limited
Trading Rating : Investor Rating :
More Ratings
Latest news on CSL LIMITED
06:02pCSL : Seqirus Begins Shipping 2018-2019 Influenza Vaccines to the U.S. Market
AQ
04:26pTHERAPEUTIC VACCINES MARKET 2018 : Global Industry Future Analysis & Growth by T..
AQ
08/14CSL : Annual Net Profit Rises, Slightly Beats Guidance
DJ
08/10CSL LIMITED : annual earnings release
08/09CSL : MILITARY $33,436 Federal Contract Awarded to CSL Behring
AQ
07/10GLENMARK PHARMACEUTICALS : Announces Exclusive Licensing Agreement with Seqirus ..
AQ
07/10CSL : Behring, Leader in Rare Diseases, Hosts a Symposium on CIDP and Presents 7..
AQ
06/28CSL : MILITARY $27.51 Million Federal Contract Awarded to Seqirus
AQ
06/20CSL : Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from th..
AQ
06/04CSL : Behring - IDELVION Newly Approved 3500 IU Vial to Provide Convenience to P..
AQ
More news
Sector news : Biopharmaceuticals
03:40pGLAXOSMITHKLINE : to Close Skincare Factory in Ireland
DJ
02:44pBASF : Bayer says can begin integration of Monsanto
RE
01:52pREGENERON PHARMACEUTICALS : Teva Report Positive Phase 3 Fasinumab Results
DJ
12:49pPFIZER : BioNTech in $425 Million Flu Vaccine Collaboration
DJ
11:43aBAYER : Shares Suffer as Bad News Mounts Up
DJ
More sector news : Biopharmaceuticals
Latest Tweets
08:09pCarlisle Companies, Inc. $CSL to Issue Quarterly Dividend of $0.40 on Septemb.. 
09:44aLISTEN: + take CSL’s pulse, try online fashion on for size and tackle some .. 
09:12aMixed bag of results as Fairfax Media, Wesfarmers, CSL and Woodside Petroleum..
2
07:20aAustralia’s CSL has stunned the market by revealing that it has started on th..
1
08/15Carlisle Companies $CSL Lifted to “Buy” at Zacks Investment Research  
More tweets
Qtime:228
News from SeekingAlpha
08/15CSL Ltd. ADR 2018 Q4 - Results - Earnings Call Slides 
02/14CSL Ltd. ADR 2018 Q2 - Results - Earnings Call Slides 
2017CSL (CSLLY) Investor Presentation - Slideshow 
2017CSL Limited Leader In High Growth Plasma Sales To China 
2017CSL reports Q2 results 
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 151 $
Spread / Average Target -2,8%
EPS Revisions
Managers
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
John Shine Chairman
David Mark Lamont Chief Financial Officer
Andrew Cuthbertson Chief Scientific Officer
Charmaine Gittleson Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED51.86%70 322
BIOGEN6.95%69 222
ALEXION PHARMACEUTICALS-3.57%26 672
BIOMARIN PHARMACEUTICAL14.18%18 317
GRIFOLS-1.78%16 905
WUXI BIOLOGICS CAYMAN INC--.--%12 325